Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 18, 2025
Transactions
13
Purchases
0
Sales
13
Purchase value
$0.00
Sale value
$3.16M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Steven B. BinderDirector
4Rule 10b5-1 plan disclosed
Filed Sep 28, 2026Period of report Sep 25, 20260001193125-26-405736
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 25, 2026
Common Stock, $0.01 Par ValueF1F2
39,051
$3.29
$128.48K
713,258
Direct
Filing footnotes · 2
F1Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
F2The weighted average sales price of the reported transaction was $3.29 based on a range of prices between $3.20 and $3.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Filed Sep 14, 2026Period of report Sep 10, 20260001193125-26-391003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 10, 2026
Common Stock, $0.01 Par ValueF1F2
33,558
$3.81
$127.86K
752,309
Direct
Filing footnotes · 2
F1Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
F2The weighted average sales price of the reported transaction was $3.81 based on a range of prices between $3.76 and $3.87. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Filed Aug 10, 2026Period of report Aug 7, 20260001193125-26-343016
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 7, 2026
Common Stock, $0.01 Par ValueF2F1
39,051
$4.06
$158.55K
785,867
Direct
Filing footnotes · 2
F1Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
F2The weighted average sales price of the reported transaction was $4.06 based on a range of prices between $3.86 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Filed Jul 17, 2026Period of report Jul 15, 20260001193125-26-308131
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 17, 2026
Common Stock, $0.01 Par ValueF4F3
24,109
$4.05
$97.64K
797,554
Direct
Filing footnotes · 5
F1A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
F2Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F3Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
F4The weighted average sales price of the reported transaction was $4.05 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Filed Jul 17, 2026Period of report Jul 15, 20260001193125-26-308129
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 17, 2026
Common Stock, $0.01 Par ValueF4F3
52,485
$4.06
$213.09K
824,918
Direct
Filing footnotes · 5
F1A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
F2Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F3Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
F4The weighted average sales price of the reported transaction was $4.06 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Filed May 13, 2026Period of report May 11, 20260001193125-26-222311
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMay 12, 2026
Common Stock, $0.01 Par ValueF2F3
16,940
$3.29
$55.73K
808,008
Direct
Filing footnotes · 3
F1Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022.
F2Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
F3The weighted average sales price of the reported transaction was $3.29 based on a range of prices between $3.25 and $3.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Filed May 13, 2026Period of report May 11, 20260001193125-26-222310
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMay 12, 2026
Common Stock, $0.01 Par ValueF2F3
3,033
$3.29
$9.98K
826,299
Direct
Filing footnotes · 3
F1Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022.
F2Transaction occurred pursuant to Rule 10b5-1 Plan established August 27, 2025.
F3The weighted average sales price of the reported transaction was $3.29 based on a range of prices between $3.25 and $3.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Michael CastagnaDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Dec 19, 2025Period of report Dec 17, 20250001193125-25-327227
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 17, 2025
Common Stock, $0.01 Par ValueF1F2
65,804
$6.01
$395.48K
2,504,792
Direct
Filing footnotes · 2
F1Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025.
F2The weighted average sales price of the reported transaction was $6.01 based on a range of prices between $6.00 and $6.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Michael CastagnaDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Dec 4, 2025Period of report Dec 2, 20250001193125-25-308350
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 2, 2025
Common Stock, $0.01 Par ValueF1F2
107,920
$5.57
$601.11K
2,504,792
Direct
Filing footnotes · 2
F1Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025.
F2The weighted average sales price of the reported transaction was $5.57 based on a range of prices between $5.50 and $5.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Filed Dec 4, 2025Period of report Dec 2, 20250001193125-25-308347
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 2, 2025
Common Stock, $0.01 Par ValueF1F2
147,780
$5.57
$823.13K
841,719
Direct
Filing footnotes · 2
F1Transaction occurred pursuant to Rule 10b5-1 Plan established August 27, 2025.
F2The weighted average sales price of the reported transaction was $5.57 based on a range of prices between $5.50 and $5.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.